Li Bowen of the University of Toronto and Daniel Anderson of the Massachusetts Institute of Technology published a research paper entitled “Accelerating ionizable lipid discovery for mRNA delivery using machine learning andRead More…
The research team led by Daniel Anderson at the Massachusetts Institute of Technology has published a research paper titled “Combinatorial development of nebulized mRNA delivery formulations for the lungs” in the journalRead More…
International pharmaceutical giant Sanofi recently announced a $25 million investment over five years in MIT’s Daniel Anderson lab to support the development of next-generation mRNA delivery technology. The funding will be utilizedRead More…
A variety of vaccines have been approved to prevent COVID-19, including two mRNA vaccines, Comirnty (BNT162b2) developed by Pfizer / BioNTech and Spikevax (mRNA-1273) developed by Moderna. The mRNA vaccine has playedRead More…
Lung-related diseases, including viral infections, tumors, and hereditary diseases, pose a great threat to human life and health. However, the cure for these diseases is still limited. With the development of variousRead More…
Advantages mRNA has a unique position in gene therapy and protein therapy, combining the advantages of both therapies while circumventing the challenges faced by both. For example, the difficulty of producing multimericRead More…
In a new study, researchers from the Massachusetts Institute of Technology, the McGovern Institute for Brain Science, the Howard-Hughes Institute of Medicine, and the Broad Institute developed a platform for delivering molecularRead More…